While dabrafenib alone or in combination with trametinib demonstrated promising efficacy in BRAF V600E mutant NSCLC, appropriate treatment paradigms are still under investigation for non-V600E mutations29,30. Here, BRAF is linked to non-small cell lung carcinoma.